ArticleScientific reports2025
Development of a prognostic prediction model based on damage-associated molecular pattern for colorectal cancer applying bulk RNA-seq analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Single-cell immune subtyping of basophils in head and neck squamous cell carcinoma and a prognostic model based on bulk RNA sequencing.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Koumine inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss via suppression of the MAPK signaling pathways.Scientific reports · 2026Article
- Integrating bulk RNA-seq and ScRNA-seq to identify manganese metabolism-related subtypes and immunoregulatory mechanisms in liver hepatocellular carcinoma.Open life sciences · 2026Article
- Trigger Points of Necroptosis (RIPK1, RIPK3, and MLKL)-Promising Horizon or Blind Alley in Therapy of Colorectal Cancer?International journal of molecular sciences · 2025Review
- Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aims to develop a risk model for the prognostic prediction for colorectal cancer (CRC) patients according to the phenotype related to damage-associated molecular patterns (DAMPs). The data were sourced from the Cancer Genome Atlas (TCGA) and cBioportal databases. The DAMP score was calculated based on the TCGA cohort data using the "ssGSEA" method. Differentially expressed genes (DEGs) identified by the "limma" package were compressed by performing Lasso Cox regression analysis using the "glmnet" package. Subsequently, biomarkers obtained were used to construct a risk model and a nomogram. The CRC subjects were divided by the median RiskScore into low- and high-risk groups. Kaplan-Meier (KM) survival analysis was conducted, and the "timeROC" package was used for model validation. The "estimate" package, "MCP-COUNTER", "ssGSEA" and "TIDE" were employed to perform immune infiltration analyses. Drug sensitivity analysis and pathway analysis were conducted using the "pRRophetic" package and "ssGSEA", respectively. According to the results, cancer-adjacent samples showed higher DAMP score and immune cell infiltration, lower tumor purity, and a better prognosis. Nine biomarkers (PAH, SIGLEC14, MMP1, JAKMIP1, FCGR3B, KCNT1, SLC2A3, SLC11A1, and HOXC4) were determined to build a reliable risk model, which showed a relatively high AUC value. Notably, patients classified by the model into the high-risk group had a worse prognostic outcome. Furthermore, a nomogram was constructed, and both the nomogram and RiskScore demonstrated a strong predictive power. The results of immune infiltration and drug sensitivity analysis showed higher immune infiltration and greater immunotherapy benefit in the low-risk group. Also, the low-risk group was enriched in immune-related pathways. We developed a reliable DAMP signature for CRC, contributing to the diagnosis and treatment of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.